Clinical Report: Characteristics and Outcomes of Salivary Secretory Carcinoma

Overview

This study analyzes the clinical and pathological features of salivary secretory carcinoma (SSC) in pediatric and young adult populations, revealing a higher median Ki-67 labeling index and a recurrence rate of 18.2% in younger patients. The findings suggest that SSC may exhibit a broader biological spectrum than previously understood.

Background

Salivary secretory carcinoma is a rare malignancy primarily affecting the parotid gland, often misclassified due to its resemblance to other salivary gland tumors. Understanding its clinical behavior in younger populations is crucial for accurate diagnosis and treatment. This study addresses the gap in age-specific outcome data for SSC, particularly in pediatric and young adult patients.

Data Highlights

Key Findings

• All younger patients presented with parotid tumors.
• The median Ki-67 labeling index was significantly higher in younger patients compared to older patients (15.0% vs 7.5%).
• The pooled recurrence rate for SSC was found to be 18.0%.
• Lymph node metastasis occurred in 10.0% of evaluable cases.
• The recurrence rate in the young subgroup was consistent with pooled estimates at 18.2%.

Clinical Implications

Clinicians should be aware of the potential for higher recurrence rates and aggressive behavior of SSC in younger patients. Accurate molecular diagnostics are essential for distinguishing SSC from other salivary gland tumors, particularly in pediatric populations. Regular follow-up and monitoring for recurrence are recommended in this demographic.

Conclusion

The findings highlight the need for systematic outcome assessments in pediatric and young adult patients with SSC, as they may exhibit more aggressive disease characteristics than previously recognized.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- Case Report: A rare pediatric case of secretory carcinoma of the parotid gland with high-grade components misdiagnosed as pleomorphic adenoma
2. conexiant, 2024 -- Most Salivary Gland Neoplasms Found to Be Benign in Single-Center Study
3. The Journal of Clinical Endocrinology & Metabolism, 2024 -- Clinical and Molecular Characteristics of Sellar Neurocytoma: A Retrospective Analysis
4. Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up - PMC
5. Clinical Rheumatology — Comprehensive Evaluation of Juvenile Sjögren's Disease
6. Practical pathological methods for reliable diagnosis of secretory carcinomas of the salivary gland
7. Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up - PMC
8. https://www.oregon.gov/oha/HPA/DSI-HERC/MembersOnly/7.5f%20NCCN%201.2026%20head-and-neck.pdf
9. Natural history of salivary gland secretory carcinoma: A REFCOR study. - ScienceDirect
10. Secretory carcinoma of the salivary gland: a multi-institutional clinicopathologic study of 90 cases with emphasis on grading and prognostic factors - PMC
11. Salivary Gland Secretory Carcinoma; Review of 13 Years World‐Wide Experience and Meta‐Analysis - Yosefof - 2024 - The Laryngoscope - Wiley Online Library
12. FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors | FDA
13. Conversion Surgery After Administration of a TRK Inhibitor for Unresectable Parotid Gland Secretory Carcinoma - Nagano - 2025 - Head & Neck - Wiley Online Library
14. Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies - PMC